Publications by authors named "Markus Heep"

Claim this Profile
I
Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial.
John R Perfect, Oliver A Cornely, Markus Heep, Luis Ostrosky-Zeichner, Kathleen M Mullane

Mycoses· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of daptomycin as first-line treatment for complicated skin and soft tissue infections in elderly patients: an open-label, multicentre, randomized phase IIIb trial.
Alexander Konychev, Markus Heep, Rose K C Moritz, Alexander Kreuter, Alexander Shulutko

Drugs Aging· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daptomycin use in patients with osteomyelitis: a preliminary report from the EU-CORE(SM) database.
R Andrew Seaton, Konstantinos N Malizos, Pierluigi Viale, Panagiotis Gargalianos-Kakolyris, Teresa Santantonio, Markus Heep

J Antimicrob Chemother· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daptomycin for the treatment of infective endocarditis: results from a European registry.
Pascal M Dohmen, Achyut Guleri, Alessandro Capone, Riccardo Utili, R Andrew Seaton, Markus Heep

J Antimicrob Chemother· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria.
Gary J Noel, Richard S Strauss, Karen Amsler, Markus Heep, Rienk Pypstra

Antimicrob Agents Chemother· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy.
Karen Bush, Markus Heep, Mark J Macielag, Gary J Noel

Expert Opin Investig Drugs· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus.
Peter A Warn, Andrew Sharp, Juan Mosquera, Jochen Spickermann, Anne Schmitt-Hoffmann, Markus Heep

J Antimicrob Chemother· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers.
Anne Schmitt-Hoffmann, Brigitte Roos, Markus Heep, Michael Schleimer, Erhard Weidekamm

Antimicrob Agents Chemother· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers.
Anne Schmitt-Hoffmann, Brigitte Roos, Jürgen Maares, Markus Heep, Jochen Spickerman

Antimicrob Agents Chemother· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis